disclosing and providing information; adjust the existing ways to comply with any previously applicable instructions and requirements; train personnel to be able to respond to a collection of information; search data sources; complete and review the collection of information; and transmit or otherwise disclose the information.

Respondents/Affected Entities: Leadacid battery manufacturing plants/grid casting facilities, paste mixing facilities, three-process operation facilities, leadoxide manufacturing facilities, lead reclamation facilities, and other leademitting operations.

Estimated Number of Respondents: 52.

Frequency of Response: Initial and semiannual, if using CEMS.

Estimated Total Annual Hour Burden: 4,053 hours (rounded).

Estimated Total Capital and Operations & Maintenance (O & M) Annual Costs: \$11,700 which includes no annualized capital/startup costs.

Changes in the Estimates: There is an increase of 3,930 hours in the total estimated burden currently identified in the OMB Inventory of Approved ICR Burdens. The net increase in labor burden from the most recently approved ICR is due to the inclusion of monitoring and recordkeeping requirements for sources using scrubbing systems in the burden calculation which had been omitted. We have determined that 25 percent of the sources (i.e., 13 sources) would be required to monitor and record pressure drop across the scrubbing systems every 15 minutes. The inclusion of these rule requirements resulted in a significant net increase in labor hours even when the number of sources significantly decreased (i.e., from 82 to 52) from the most recently approved ICR. The decrease in the number of sources did not affect the labor hours significantly because no periodic reports are required for existing sources. However, the decrease in the number of sources had a net decrease on the operation and maintenance costs associated with continuous monitoring devices when compared to the most recently approved ICR

Dated: June 13, 2003.

Doreen Sterling,

Acting Director, Collection Strategies Division.

[FR Doc. 03–16030 Filed 6–24–03; 8:45 am] BILLING CODE 6560–50–P

ENVIRONMENTAL PROTECTION AGENCY

[OPP-2003-0192; FRL-7314-9]

FIFRA Scientific Advisory Panel; Notice of Cancellation of Public Meeting

AGENCY: Environmental Protection Agency (EPA). **ACTION:** Notice.

SUMMARY: The July 16, 2003, Federal Insecticide, Fungicide, and Rodenticide Act Scientific Advisory Panel (FIFRA SAP) meeting to consider and review issues concerned with ensuring data quality for in vitro tests used as alternatives to animal studies for regulatory purposes has been cancelled. A new meeting will be rescheduled within the next several months and will be announced in the Federal Register. For further information, please notify the Designated Federal Official (DFO) listed under FOR FURTHER INFORMATION CONTACT or see the Federal Register of May 30, 2003 (68 FR 32490) (FRL-7311-3).

FOR FURTHER INFORMATION CONTACT:

Myrta Christian, Designated Federal Official, Office of Science Coordination and Policy (7201M), Environmental Protection Agency, 1200 Pennsylvania Ave., NW., Washington, DC 20460; telephone number: (202) 564–8450; fax number: (202) 564–8382; e-mail address: christian.myrta@epa.gov.

List of Subjects

Environmental protection, Pesticides and pests.

Dated: June 19, 2003.

Joseph J. Merenda,

Director, Office of Science Coordination and Policy.

[FR Doc. 03–16036 Filed 6–24–03; 8:45 am] BILLING CODE 6560–50–S

ENVIRONMENTAL PROTECTION AGENCY

[OPP-2003-0217; FRL-7314-6]

Imazalil; Availability of Risk Assessment

AGENCY: Environmental Protection Agency (EPA). **ACTION:** Notice.

SUMMARY: This notice announces the availability of documents that were developed as part of EPA's process for making pesticide reregistration eligibility decisions under the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). These documents are the

occupational and ecological risk assessments and related documents for imazalil. This notice also starts a 60-day public comment period for the risk assessments. Comments are to be limited to issues directly associated with imazalil and raised by the occupational and ecological risk assessments or other documents placed in the docket. By allowing access and opportunity for comments on the risk assessments, EPA is seeking to strengthen stakeholder involvement and help ensure that our decisions under FIFRA are transparent and based on the best available information. The Agency cautions that the risk assessments for imazalil are revised; however, further refinements may be appropriate. Risk assessments reflect only the work and analysis conducted as of the time they were produced and it is appropriate that, as new information becomes available and/or additional analyses are performed, the conclusions they contain may change.

DATES: Comments, identified by the docket ID number OPP–2003–0217, must be received on or before August 25, 2003.

ADDRESSES: Comments may be submitted electronically, by mail, or through hand delivery/courier. Follow the detailed instructions as provided in Unit I. of the SUPPLEMENTARY INFORMATION.

FOR FURTHER INFORMATION CONTACT: Cecelia Watson, Special Review and Reregistration Division (7508C), Office of Pesticide Programs, Environmental Protection Agency, 1200 Pennsylvania Ave., NW., Washington, DC 20460– 0001; telephone number: (703) 305– 4329; e-mail address: watson.cecelia@epa.gov.

SUPPLEMENTARY INFORMATION:

I. General Information

A. Does this Action Apply to Me?

This action is directed to the public in general, nevertheless, a wide range of stakeholders will be interested in obtaining the revised risk assessments and submitting risk management comments on imazalil, including environmental, human health, and agricultural advocates; the chemical industry; pesticide users; and members of the public interested in the use of pesticides on food. As such, the Agency has not attempted to specifically describe all the entities potentially affected by this action. If you have any questions regarding the applicability of this action to a particular entity, consult the person listed under FOR FURTHER INFORMATION CONTACT.